Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage
By S. Slichter, R. Kaufman, S. Assmann, J. McCullough, D. Triulzi, R. Strauss, T. Gernsheimer, P. Ness, M. Brecher, C. Josephson and 15 more. New England Journal of Medicine, 2010
605 citations recorded by the source corpus.
BACKGROUND We conducted a trial of prophylactic platelet transfusions to evaluate the effect of platelet dose on bleeding in patients with hypoproliferative thrombocytopenia. METHODS We randomly assigned hospitalized patients undergoing hematopoietic stem-cell transplantation or chemotherapy for hematologic cancers or solid tumors to receive prophylactic platelet transfusions at a low dose, a medium dose, or a high dose (1.1×1011, 2.2×1011, or 4.4×1011 platelets per square meter of body-surface area, respectively), when morning platelet counts were 10,000 per cubic millimeter or lower. Clinical signs of bleeding were assessed daily. The primary end point was bleeding of grade 2 or higher (as defined on the basis of World Health Organization criteria). RESULTS In the 1272 patients who received at least one platelet transfusion, the primary end point was observed in 71%, 69%, and 70% of the patients in the low-dose group, the medium-dose group, and the high-dose group, respectively (differences were not significant). The incidences of higher grades of bleeding, and other adverse events, were similar among the three groups. The median number of platelets transfused was significantly lower in the low-dose group (9.25×1011) than in the medium-dose group (11.25×1011) or the high-dose group (19.63×1011) (P = 0.002 for low vs. medium, P<0.001 for high vs. low and high vs. medium), but the median number of platelet transfusions given was significantly higher in the low-dose group (five, vs. three in the medium-dose and three in the high-dose group; P<0.001 for low vs. medium and low vs. high). Bleeding occurred on 25% of the study days on which morning platelet counts were 5000 per cubic millimeter or lower, as compared with 17% of study days on which platelet counts were 6000 to 80,000 per cubic millimeter (P<0.001). CONCLUSIONS Low doses of platelets administered as a prophylactic transfusion led to a decreased number of platelets transfused per patient but an increased number of transfusions given. At doses between 1.1×1011 and 4.4×1011 platelets per square meter, the number of platelets in the prophylactic transfusion had no effect on the incidence of bleeding. (ClinicalTrials.gov number, NCT00128713.)
Subfields: Biochemistry, Critical Care and Intensive Care Medicine, Hematology
View Paper: https://www.semanticscholar.org/paper/cd9b0249c7ba0e760961a5df2d867339046554eb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- B. Djulbegovic
- T. Gernsheimer
- R. Kaufman
- S. Kleinman
- A. Tinmouth
- K. Capocelli
- M. Cipolle
- Barbara O’Malley
Citations in the corpus
- Platelet Transfusion: A Clinical Practice Guideline From the AABB (2015, positive): “The Platelet Dose study (18) established that patients receiving low-dose prophylactic platelet transfusions for a morning platelet count of 10 × 10(9) cells/L or less had the same bleeding risk as patients receiving standard- or high-dose platelets.”
- Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, neutral): “at steady state after platelet transfusion [385].”